Drug Profile
CTX 100
Alternative Names: ETX 100; Hyaluronan inhalation - Actelion Pharmaceuticals; Hyaluronic acid inhalation - Actelion PharmaceuticalsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CoTherix
- Class Anti-inflammatories
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alpha 1-antitrypsin deficiency; Asthma
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
- 14 Apr 2005 Discontinued - Phase-I for Alpha 1-antitrypsin deficiency in Netherlands (Inhalation)
- 14 Apr 2005 Discontinued - Phase-I for Asthma in Netherlands (Inhalation)